However, elevation of circulating IL‐6 levels on hepcidin and its modulation of iron availability and red blood cell production may limit the compensatory erythropoietic response in COVID‐19 patients [41, 42, 43, 44]. The gene discussed is HAMP; the disease is COVID-19.